Effect of a thymic factor on the concentration of a factor VIIi inhibitor in a patient with treated Hodgkin's disease
Richard, C.; Sedano, C.; Cuadrado, M.A.; Iriondo, A.; Bello, C.; Gandarillas, M.A.; Zubizarreta, A.
Thrombosis and Haemostasis 55(2): 299-300
1986
ISSN/ISBN: 0340-6245 PMID: 3087005 Document Number: 270382
Document emailed within 1 workday
Related Documents
Takahashi, I.; Furuta, M.; Mizuno, S.; Takamatsu, J.; Kamiya, T. 1993: Effect of substrate and diluent for factor VIIi activity in highly purified factor VIIi concentrate and patient plasma infused factor VIIi concentrate Rinsho Byori. Japanese Journal of Clinical Pathology 41(7): 825-830Muntean, W. 1984: Purified complex of factor VIII coagulant moiety and phospholipid: high factor VIII coagulant activity in factor VIII inhibitor plasma Wiener Klinische Wochenschrift 96(22): 829-832
Tham, C.J.; Trew, M.; Brager, N. 1999: Abnormal clotting and production of factor VIIi inhibitor in a patient treated with venlafaxine Canadian Journal of Psychiatry. Revue Canadienne de Psychiatrie 44(9): 923-924
Brown, J.E.; Carton, C.L.; Hougie, C. 1981: The effect of naturally occurring antibodies to factor VIIi on an immunoradiometric assay for factor VIIi coagulant antigen. Observation on a cross-reacting material-positive (CRM+) hemophiliac with a factor VIIi inhibit Journal of Laboratory and Clinical Medicine 97(1): 65-71
Mahasandana, C.; Suvatte, V.; Püng-amritt, P.; Tuchinda, S. 1979: Von Willebrand's disease: studies of platelet functions, factor VIII procoagulant activity (F VIII C) and factor VIII-related antigen (F VIII RAg) in three families Southeast Asian Journal of Tropical Medicine and Public Health 10(2): 243-247
Brettler, D.B.; Forsberg, A.D.; Levine, P.H.; Aledort, L.M.; Hilgartner, M.W.; Kasper, C.K.; Lusher, J.M.; McMillan, C.; Roberts, H. 1989: The use of porcine factor VIII concentrate (Hyate:C) in the treatment of patients with inhibitor antibodies to factor VIII. A multicenter US experience Archives of Internal Medicine 149(6): 1381-1385
Teitel, J.M.; Lau, H.K.; Garvey, M.B. 2002: Discrepancies in measured factor VIIi activity in patients treated with factor VIIi concentrate of human or porcine origin Thrombosis and Haemostasis 88(1): 159-160
Liebe, S. 1982: Activation of the antihemophilic globulin a (factor VIII). 2. Effect of ampholine on the course of blood coagulation and the molecular conformation of factor VIIi Zeitschrift für die Gesamte Innere Medizin und ihre Grenzgebiete 37(4): 110-116
Akahori, M.; Yamane, T.; Hino, M.; Ohta, K.; Takubo, T.; Samori, T.; Tatsumi, N. 1999: Non-hemophilic patient with inhibitor against factor VIIi produced after the second delivery Rinsho Byori. Japanese Journal of Clinical Pathology 47(9): 891-895
Villani, F.; Dell'Oca, I.; De Maria, P.; Viola, G.; Di Russo, A.; Viviani, S.; Bonfante, V. 1999: Lung function and serum concentration of tumor necrosis factor-alpha, interleukin-6 and fibronectin in patients treated with ABVD chemotherapy followed by radiotherapy for mediastinal Hodgkin's disease Anticancer Research 19(5c): 4475-4479
Kamphuisen, P.W.; Eikenboom, H.C.; Rosendaal, F.R.; Bertina, R.M. 2001: High concentration of coagulation factor VIIi as a risk factor for thrombosis Nederlands Tijdschrift Voor Geneeskunde 145(46): 2213-2217
Tran, T.H.; Duckert, F. 1983: Dissociation of factor VIIi procoagulant antigen VIII:CAg and factor VIIi related antigen VIIIR:Ag by EDTA - influence of divalent cation on the binding of VIII:CAg and VIIIR:Ag Thrombosis and Haemostasis 50(2): 547-551
Mazurier, C.; Meyer, D. 1996: Factor VIII binding assay of von Willebrand factor and the diagnosis of type 2N von Willebrand disease--results of an international survey. On behalf of the Subcommittee on von Willebrand Factor of the Scientific and Standardization Committee of the ISTH Thrombosis and Haemostasis 76(2): 270-274
Allersma, D.P.; Smid, W.M.; van der Does, J.A.; van der Meer, J.; Briët, E. 1996: Effects of chronic factor VIII substitution on immune parameters in HIV seronegative haemophiliacs: a comparison between cryoprecipitate and factor VIII concentrate Thrombosis and Haemostasis 75(2): 261-266
Lee, C.A.; Owens, D.; Bray, G.; Giangrande, P.; Collins, P.; Hay, C.; Gomperts, E.; Schroth, P.; Barrowcliffe, T. 1999: Pharmacokinetics of recombinant factor VIIi (recombinate) using one-stage clotting and chromogenic factor VIIi assay Thrombosis and Haemostasis 82(6): 1644-1647
Gatti, L.; Mannucci, P.M. 1984: Use of porcine factor VIII in the management of seventeen patients with factor VIII antibodies Thrombosis and Haemostasis 51(3): 379-384
Girolami, A.; de Marco, L.; Fabris, F.; Casonato, A. 1977: Platelet adhesiveness and aggregation in combined factor V and factor VIIi deficiency and in combined factor VIi and factor VIIi deficiency Folia Haematologica 104(5): 663-669
Mauser-Bunschoten, E.P.; Roosendaal, G.; Bruin, M.; van Dijken, P.J. 1990: Disappearance of factor VIIi antibodies upon frequent administration of factor VIIi Folia Haematologica 117(4): 533-537
Schoppmann, A.; Waytes, A.T. 1996: Factor VIIi inhibitor and severity of hemophilia Thrombosis and Haemostasis 76(2): 280-281
Błońska, B.; Czaplicki, J.; Pesić, M.C.; Kamińska, E.; Soblik-Górowska, E.; Czarnecki, J. 1989: Do active substances of thymus influence the processes of aging? VIII. Cerebral superoxide dismutase activity and malonyl dialdehyde concentration in aging mice treated with embryonal and early fetal thymic calf extracts (ETCE) and mature calf thymic extracts (thymex L and TFX) Acta Medica Polona 30(3-4): 169-173